Related Experiment Video

Updated: Feb 18, 2026

Mouse Complete Stasis Model of Inferior Vena Cava Thrombosis
04:34

Mouse Complete Stasis Model of Inferior Vena Cava Thrombosis

Published on: June 15, 2011

19.0K

Galectin-3 and Venous Thromboembolism Incidence: the Atherosclerosis Risk in Communities (ARIC) Study

Oluwaseun E Fashanu1, Susan R Heckbert2, David Aguilar3

  • 1Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.

Research and Practice in Thrombosis and Haemostasis
|November 21, 2017
PubMed

Insights

Higher levels of galectin-3, an inflammatory biomarker, are linked to an increased risk of venous thromboembolism (VTE). This association was observed in a large cohort study, suggesting galectin-3 as a potential VTE risk indicator.

Area of Science:

  • Biomarkers and Cardiovascular Disease
  • Thrombosis and Hemostasis Research
  • Genetic Epidemiology

Background:

  • Galectin-3 is an inflammatory biomarker implicated in heart failure and thrombosis.
  • The link between galectin-3 and venous thromboembolism (VTE) requires further investigation.

Purpose of the Study:

  • To prospectively examine the association between plasma galectin-3 levels and VTE incidence.
  • To investigate the role of the *LGALS3* rs4644 single nucleotide polymorphism (SNP) in VTE risk.

Main Methods:

  • Plasma galectin-3 was measured in 9,916 participants of the Atherosclerosis Risk in Communities (ARIC) study.
  • Venous thromboembolism (VTE) events were identified through 2013, with a median follow-up of 13.9 years.
  • Cox regression analysis was used to estimate hazard ratios, with replication in the Cardiovascular Health Study (CHS).

Main Results:

  • In the ARIC cohort, VTE incidence increased across galectin-3 quintiles (p-trend = 0.005), even after adjusting for multiple risk factors.
  • While not replicated in the CHS, a meta-analysis of both studies showed a pooled hazard ratio of 1.10 (95% CI: 1.00–1.22) for a 1 SD increase in log galectin-3.
  • The *LGALS3* rs4644 C allele was associated with higher galectin-3 levels and increased VTE risk in white participants.

Conclusions:

  • Plasma galectin-3 levels are positively associated with the incidence of venous thromboembolism (VTE).
  • Galectin-3 may serve as a predictive biomarker for VTE risk.
Abstract

Keywords:
Galectin-3GeneProspectiveThrombosisVenous thromboembolism

More Related Videos

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

3.3K
Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography06:44

Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography

Published on: April 13, 2018

10.5K

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
388
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
504
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
362
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
460
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
278
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
587